Skip to main content
FERMENTA BIOTECH LIMITED logo

FERMENTA BIOTECH LIMITED — Investor Relations & Filings

Ticker · FERMENTA ISIN · INE225B01021 LEI · 335800VNTNWW8G1U9314 BSE.NS Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2021-11-12 Regulatory Filings
Country IN India
Listing BSE.NS FERMENTA

About FERMENTA BIOTECH LIMITED

https://fermentabiotech.com

Fermenta Biotech Limited is a specialized biotechnology company primarily focused on the development and manufacture of Vitamin D3 (Cholecalciferol). As one of the few vertically integrated manufacturers globally, the company produces Vitamin D3 for diverse applications, including pharmaceuticals, dietary supplements, human nutrition, and animal feed. Beyond its core Vitamin D3 portfolio, the company offers a range of specialty enzymes, particularly for the synthesis of beta-lactam antibiotics, and provides environmental solutions through its biotechnology expertise. Fermenta Biotech emphasizes high-quality standards, maintaining various international certifications for its manufacturing facilities. Its product offerings extend to premixes and value-added formats designed to meet specific formulation requirements. The company serves a global clientele, leveraging its research and development capabilities to innovate in the fields of nutrition and biotechnology.

Recent filings

Filing Released Lang Actions
Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the earnings conference call is scheduled ....
Regulatory Filings Classification · 95% confidence The document is an official communication from Fermenta Biotech Limited to the stock exchange (BSE Limited) informing about an upcoming earnings conference call scheduled to discuss the financial performance for the quarter and half year ended September 30, 2021. It includes details about the call date, time, participants, and dial-in numbers. The document does not contain actual financial results or detailed financial statements but is an announcement of the earnings call event. According to the classification rules, such a document is best classified as a Call Transcript (CT) category if it contained the full transcript, but since this is only an invitation/announcement of the call, it is not a transcript. It is also not an Earnings Release (ER) because it does not contain financial highlights or results. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the earnings call under SEBI regulations, since it does not fit other categories and is an official disclosure.
2021-11-12 English
We write to inform you that the Board of Directors of the Company at its meeting held on November 12, 2021, has, inter alia, approved the unaudited financial results for the quarter and ....
Regulatory Filings
2021-11-12 English
We write to inform you that the Board of Directors of the Company at its meeting held on November 12, 2021, has, inter alia, approved the unaudited financial results for the quarter and ....
Regulatory Filings
2021-11-12 English
Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our intimation given vide ....
Regulatory Filings
2021-11-03 English
We hereby inform you that meeting of the Board of Directors of the Company is scheduled to be held on Friday, November 12, 2021, inter alia, to consider and approve the unaudited financial ....
Regulatory Filings Classification · 95% confidence The document is a notice from the company to the stock exchange about the scheduling of a Board Meeting to consider and approve unaudited financial results for the quarter and half year ended September 30, 2021. It also includes information about the closure of the trading window in compliance with insider trading regulations. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is a regulatory announcement informing about an upcoming event and compliance measures, not the actual interim or quarterly report. The document length is short (2275 characters), and it serves as a notification rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2021-11-02 English
Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 ....
Regulatory Filings Classification · 95% confidence The document is a notice from the company to the stock exchange about the scheduling of a Board Meeting to consider and approve unaudited financial results for the quarter and half year ended September 30, 2021. It also includes information about the closure of the trading window in compliance with insider trading regulations. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is a regulatory announcement informing about an upcoming event and compliance measures, not the actual financial report or earnings release. The document length is short (2275 characters), and it serves as a notification rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2021-11-02 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.